HDAC2 restrains IGF2BP1-associated m6A dysregulation in cervical cancer immunotherapy resistance
Qiuhong Deng, Zhi Wang, Jine Zhao, Ning Li, Linghua Zhang, Wanxia He, Yongmei Zhang · 2026
Read HDAC2 restrains IGF2BP1-associated m6A dysregulation in cervical cancer immunotherapy resistance by Qiuhong Deng, Zhi Wang, Jine Zhao, Ning Li, Linghua Zhang, Wanxia He, Yongmei Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0355606.txt.
Description
Qiuhong Deng leads a 2026 PLOS ONE study of why cervical cancer resists immunotherapy, treatment that frees the immune system to attack tumors. A protein called IGF2BP1 reads a chemical tag on gene messages, named m6A, and was suspected of helping tumors dodge immune attack. Its control was unknown.
Across datasets and four cancer cell lines, IGF2BP1 ran high and tracked with poor survival. Silencing it slowed growth and made tumors respond better to a checkpoint drug, with more killer T cells entering and firing. Another protein, HDAC2, normally keeps IGF2BP1 repressed by cleaning tags off its gene switch. Losing HDAC2 frees it. Targeting the axis partly restored drug effect.
Catalog record
| CREATOR | Qiuhong Deng, Zhi Wang, Jine Zhao, Ning Li, Linghua Zhang, Wanxia He, Yongmei Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44318 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |